PDS Biotechnology Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $5.55
- Today's High:
- $5.88
- Open Price:
- $5.88
- 52W Low:
- $2.89
- 52W High:
- $13.65
- Prev. Close:
- $5.89
- Volume:
- 556375
Company Statistics
- Market Cap.:
- $186.44 million
- Book Value:
- 1.051
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -50.33%
- Return on Equity TTM:
- -113.88%
Company Profile
PDS Biotechnology Corp had its IPO on 2015-10-01 under the ticker symbol PDSB.
The company operates in the Healthcare sector and Biotechnology industry. PDS Biotechnology Corp has a staff strength of 26 employees.
Stock update
Shares of PDS Biotechnology Corp opened at $5.88 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $5.55 - $5.88, and closed at $5.59.
This is a -5.09% slip from the previous day's closing price.
A total volume of 556,375 shares were traded at the close of the day’s session.
In the last one week, shares of PDS Biotechnology Corp have slipped by -7.45%.
PDS Biotechnology Corp's Key Ratios
PDS Biotechnology Corp has a market cap of $186.44 million, indicating a price to book ratio of 5.5734 and a price to sales ratio of 0.
In the last 12-months PDS Biotechnology Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-48141624. The EBITDA ratio measures PDS Biotechnology Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PDS Biotechnology Corp’s operating margin was 0% while its return on assets stood at -50.33% with a return of equity of -113.88%.
In Q2, PDS Biotechnology Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
PDS Biotechnology Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PDS Biotechnology Corp’s profitability.
PDS Biotechnology Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.3338. Its price to sales ratio in the trailing 12-months stood at 0.
PDS Biotechnology Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $63.75 million
- Total Liabilities
- $7.90 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
PDS Biotechnology Corp ended 2024 with $63.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $63.75 million while shareholder equity stood at $32.44 million.
PDS Biotechnology Corp ended 2024 with $0 in deferred long-term liabilities, $7.90 million in other current liabilities, 10188.00 in common stock, $-122753230.00 in retained earnings and $0 in goodwill. Its cash balance stood at $60.62 million and cash and short-term investments were $60.62 million. The company’s total short-term debt was $112,959 while long-term debt stood at $23.25 million.
PDS Biotechnology Corp’s total current assets stands at $63.35 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $4.41 million and inventory worth $0.
In 2024, PDS Biotechnology Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, PDS Biotechnology Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.59
- 52-Week High
- $13.65
- 52-Week Low
- $2.89
- Analyst Target Price
- $19.29
PDS Biotechnology Corp stock is currently trading at $5.59 per share. It touched a 52-week high of $13.65 and a 52-week low of $13.65. Analysts tracking the stock have a 12-month average target price of $19.29.
Its 50-day moving average was $5.53 and 200-day moving average was $7.19 The short ratio stood at 6.75 indicating a short percent outstanding of 0%.
Around 436.7% of the company’s stock are held by insiders while 2512% are held by institutions.
Frequently Asked Questions About PDS Biotechnology Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.